Sale

Thrombin Market

Global Thrombin Market Size, Share, Growth, Trends, Forecast: By Product: Bovine Thrombin, Human Thrombin, Recombinant Thrombin; By Dosage Form: Powder Form, Solution Form; By End User: Hospitals, Diagnostic Centre and Clinics, Academics and Research Institutes, Others; Regional Analysis; Supplier Landscape; 2024-2032

Global Thrombin Market Outlook

The global thrombin market size was valued at USD 665 million in 2023, driven by the increasing prevalence of blood disorders such as hemophilia across the globe. The market is expected to grow at a CAGR of 5.50% during the forecast period of 2024-2032, with the values likely to rise from USD 701.3 million in 2024 to USD 1075.9 million by 2032.

 

Global Thrombin Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Thrombin Market Overview

Thrombin, also known as coagulation factor II, is a serine protease that regulates hemostasis and maintains blood coagulation. It is naturally produced in humans and is involved in the coagulation cascade. There are three thrombin products: bovine thrombin, human thrombin, and recombinant thrombin. All of them are approved by the Food and Drug Administration (FDA) for topical application as a solution, in combination with fibrinogen as a glue, or sprayed into a mist. As a hemostatic agent, thrombin can minimize blood loss during surgical procedures.

 

The thrombin market demand is driven by the rising incidence of hemophilia, an inherited bleeding disorder. It is estimated that 1 in every 6000-10,000  males have this bleeding disorder. Approximately 30,000 – 33,000 males are living with hemophilia in the United States, with the highest prevalence found in the Midwestern and Northeastern states.  Another key driver is the extensive application of thrombin in the healthcare sector, owing to the growing prevalence of trauma cases. Moreover, the advancement in the healthcare infrastructure as well as the rising disposable income of the population is projected to contribute to the market growth in the forecast period.

 

Intensive Research to Expedite Thrombin Market Growth

Thrombin is extensively used in the hemostatic field. It can provide a direct clotting effect on the exposed blood, controlling minor oozing and bleeding during surgery. Intensive research activities by academic institutes and pharmaceutical companies revealed several therapeutic applications of thrombin including burn treatment, wound management, and tumor vasculature blockade therapy.

 

In November 2023, a study published in Nature,  compared active (gelatin-thrombin-based product Floseal) and passive (modified absorbable polymers powder PerClot) hemostatic agents to find their effectiveness in controlling hepatic bleeding. It was observed that Floseal (active hemostatic group) was faster to achieve homeostasis than PerClot (passive hemostatic group) which was attributed to the presence of thrombin component in it. The continuous research and development efforts to find novel therapeutics and improve existing uses of thrombin are anticipated to contribute to the thrombin market share.

 

Growing Applications of Recombinant Thrombin

The regulatory health body FDA has approved many thrombin-based products including recombinant thrombin. Several drugs containing recombinant thrombin are currently undergoing clinical trials for their therapeutic homeostatic effect. In April 2023 , Baxter International Inc., announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. The new addition to its surgical portfolio was revealed at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.

 

Global Thrombin Market by Segment

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Thrombin Market Segmentation

Market Breakup by Product

  • Bovine Thrombin
  • Human Thrombin
  • Recombinant Thrombin

 

Market Breakup by Dosage Form

  • Powder Form
  • Solution Form

 

Market Breakup by End User

  • Hospitals
  • Diagnostic Centre and Clinics
  • Academics and Research Institutes
  • Others

 

Market Breakup by Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Global Thrombin Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Thrombin Market Regional Analysis

North America is experiencing significant growth in the demand for thrombin due to the increasing prevalence of blood disorders and trauma cases which requires the need for effective hemostatic agents. In addition, the robust support from government and non-government organizations is further accelerating market growth.

 

In August 2023 , Oklahoma Medical Research Foundation scientist Ray Rezaie received a USD 1.7 million grant from the National Institutes of Health (NIH) to support his work on blood clotting and the interaction of associated three molecules including thrombin. The funding will accelerate the research on mechanisms controlling clotting and inflammation, leading to promising medications for stroke, heart attack, and sepsis.

 

Europe also holds a considerable thrombin market share owing to the presence of well-established healthcare infrastructure. The existence of leading pharmaceutical companies is fuelling research and development (R&D) activities of thrombin, which is expanding the market size. In Asia Pacific, the growing population size, rising healthcare expenditure, and the increasing impetus for improved patient care are driving the market growth. The region is anticipated to offer lucrative growth opportunities for the key market players due to the surge in the adoption of thrombin-based hemostats in healthcare facilities.


Global Thrombin Market: Competitor Landscape

In October 2023 , Aronora, a clinical-stage biotech based in the United States, secured investment from an early-stage life sciences investment fund NYBC Ventures. The funds will be used to develop the lead drug candidates E-WE thrombin (AB002) and Gruticibart (AB023) and expand its manufacturing capacities. E-WE thrombin, an anticoagulant, has demonstrated positive results in phase 2a clinical trials. The increased investment in research and development by pharmaceutical companies and research organizations will improve the safety and efficacy of thrombin-based products, elevating thrombin market value in the forecast period.

 

The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

 

  • Pfizer Inc.
  • Johnson and Johnson
  • Baxter International, Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Japan Blood Products Organization
  • Mochida Pharmaceutical Co., Ltd
  • Haematologic Technologies Inc.
  • GE Healthcare
  • Hualan Biological
  • AMRESCO Inc
  • CSL Behring
  • Mallinckrodt Pharmaceuticals
  • BIOFAC A/S
  • Biomed-Lublin S.A.
  • Hualan Biological Engineering, Inc.

 

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Product
  • Dosage Form
  • End User
  • Region
Breakup by Product
  • Bovine Thrombin
  • Human Thrombin
  • Recombinant Thrombin
Breakup by Dosage Form
  • Powder Form
  • Solution Form
Breakup by End User
  • Hospitals
  • Diagnostic Centre and Clinics
  • Academics and Research Institutes
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Pfizer Inc.
  • Johnson and Johnson
  • Baxter International, Inc.
  • Shanghai RAAS Blood Products Co., Ltd.
  • Japan Blood Products Organization
  • Mochida Pharmaceutical Co., Ltd
  • Haematologic Technologies Inc.
  • GE Healthcare
  • Hualan Biological
  • AMRESCO Inc
  • CSL Behring
  • Mallinckrodt Pharmaceuticals
  • BIOFAC A/S
  • Biomed-Lublin S.A.
  • Hualan Biological Engineering, Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Thrombin Market Overview 

    3.1    Global Thrombin Market Historical Value (2017-2023) 
    3.2    Global Thrombin Market Forecast Value (2024-2032)
4    Global Thrombin Market Landscape*
    4.1    Global Thrombin Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Thrombin Product Landscape
        4.2.1     Analysis by Product
        4.1.2    Analysis by Dosage Form 
5    Global Thrombin Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
        5.2.1    Strengths
        5.2.2    Weaknesses
        5.2.3    Opportunities
        5.2.4    Threats
    5.3    Porter’s Five Forces Model 
        5.3.1    Bargaining Power of Suppliers
        5.3.2    Bargaining Power of Buyers
        5.3.3    Threat of New Entrants
        5.3.4    Threat of Substitutes
        5.3.5    Degree of Rivalry
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Thrombin Market Segmentation (2017-2032)
    6.1    Global Thrombin Market (2017-2032) by Product 
        6.1.1    Market Overview
        6.1.2    Bovine Thrombin
        6.1.3    Human Thrombin
        6.1.4    Recombinant Thrombin
    6.2    Global Thrombin Market (2017-2032) by Dosage Form
        6.2.1    Market Overview
        6.2.2    Powder Form
        6.2.3    Solution Form
    6.3    Global Thrombin Market (2017-2032) by End User
        6.3.1    Market Overview
        6.3.2    Hospitals
        6.3.3    Diagnostic Centre and Clinics
        6.3.4    Academics and Research Institutes
        6.3.5    Others
    6.4    Global Thrombin Market (2017-2032) by Region
        6.4.1    Market Overview
        6.4.2    North America 
        6.4.3    Europe
        6.4.4    Asia Pacific
        6.4.5    Latin America
        6.4.6    Middle East and Africa
7    North America Thrombin Market (2017-2032)
    7.1    North America Thrombin Market (2017-2032) by Product
        7.1.1    Market Overview
        7.1.2    Bovine Thrombin
        7.1.3    Human Thrombin
        7.1.4    Recombinant Thrombin
    7.2    North America Thrombin Market (2017-2032) by Dosage Form
        7.2.1    Market Overview
        7.2.2    Powder Form
        7.2.3    Solution Form
    7.3    North America Interventional Radiology Market (2017-2032) by Country
        7.3.1    United States of America
        7.3.2    Canada
8    Europe Thrombin Market (2017-2032)
    8.1    Europe Thrombin Market (2017-2032) by Product
        8.1.1    Market Overview
        8.1.2    Bovine Thrombin
        8.1.3    Human Thrombin
        8.1.4    Recombinant Thrombin
    8.2    Europe Thrombin Market (2017-2032) by Dosage Form
        8.2.1    Market Overview
        8.2.2    Powder Form
        8.2.3    Solution Form
    8.3    Europe Thrombin Market (2017-2032) by Country
        8.3.1    United Kingdom
        8.3.2    Germany
        8.3.3    France
        8.3.4    Italy
        8.3.5    Others
9    Asia Pacific Thrombin Market (2017-2032)
    9.1    Asia Pacific Thrombin Market (2017-2032) by Product
        9.1.1    Market Overview
        9.1.2    Bovine Thrombin
        9.1.3    Human Thrombin
        9.1.4    Recombinant Thrombin
    9.2    Asia Pacific Thrombin Market (2017-2032) by Dosage Form
        9.2.1    Market Overview
        9.2.2    Powder Form
        9.2.3    Solution Form
    9.3    Asia Pacific Cryostat Market (2017-2032) by Country
        9.3.1    China
        9.3.2    Japan
        9.3.3    India
        9.3.4    ASEAN
        9.3.5    Australia
        9.3.6    Others
10    Latin America Thrombin Market (2017-2032)
    10.1    Latin America Thrombin Market (2017-2032) by Product
        10.1.1    Market Overview
        10.1.2    Bovine Thrombin
        10.1.3    Human Thrombin
        10.1.4    Recombinant Thrombin
    10.2    Latin America Thrombin Market (2017-2032) by Dosage Form
        10.2.1    Market Overview
        10.2.2    Powder Form
        10.2.3    Solution Form
    10.3    Latin America Thrombin Market (2017-2032) by Country
        10.3.1    Brazil
        10.3.2    Argentina
        10.3.3    Mexico
        10.3.4    Others
11    Middle East and Africa Thrombin Market (2017-2032)
    11.1    Middle East and Africa Thrombin Market (2017-2032) by Product
        11.1.1    Market Overview
        11.1.2    Bovine Thrombin
        11.1.3    Human Thrombin
        11.1.4    Recombinant Thrombin
    11.2    Middle East and Africa Thrombin Market (2017-2032) by Dosage Form
        11.2.1    Market Overview
        11.2.2    Powder Form
        11.2.3    Solution Form
    11.3    Middle East and Africa Interventional Radiology Market (2017-2032) by Country
        11.3.1    Saudi Arabia
        11.3.2    United Arab Emirates
        11.3.3    Nigeria
        11.3.4    South Africa
        11.3.5    Others
12    Regulatory Framework
    12.1     Regulatory Overview
        12.1.1    US FDA
        12.1.2    EU EMA
        12.1.3    INDIA CDSCO
        12.1.4    JAPAN PMDA
        12.1.5    Others
13    Patent Analysis
    13.1    Analysis by Type of Patent
    13.2    Analysis by Publication Year
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Patent Age
    13.5    Analysis by CPC Analysis
    13.6    Analysis by Patent Valuation 
    13.7    Analysis by Key Players
14    Grants Analysis
    14.1    Analysis by year
    14.2    Analysis by Amount Awarded
    14.3    Analysis by Issuing Authority
    14.4    Analysis by Grant Application
    14.5    Analysis by Funding Institute
    14.6    Analysis by NIH Departments
    14.7    Analysis by Recipient Organization
15    Funding Analysis
    15.1    Analysis by Funding Instances
    15.2    Analysis by Type of Funding
    15.3    Analysis by Funding Amount
    15.4    Analysis by Leading Players
    15.5    Analysis by Leading Investors
    15.6    Analysis by Geography
16    Partnership and Collaborations Analysis
    16.1    Analysis by Partnership Instances
    16.2    Analysis by Type of Partnership
    16.3    Analysis by Leading Players
    16.4    Analysis by Geography
17    Supplier Landscape
    17.1    Pfizer Inc.
        17.1.1    Financial Analysis
        17.1.2    Product Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Johnson and Johnson
        17.2.1    Financial Analysis
        17.2.2    Product Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Baxter International, Inc.
        17.3.1    Financial Analysis
        17.3.2    Product Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Shanghai RAAS Blood Products Co., Ltd.
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Japan Blood Products Organization
        17.5.1    Financial Analysis
        17.5.2    Product Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Mochida Pharmaceutical Co., Ltd
        17.6.1    Financial Analysis
        17.6.2    Product Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Haematologic Technologies Inc.
        17.7.1    Financial Analysis
        17.7.2    Product Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    GE Healthcare
        17.8.1    Financial Analysis
        17.8.2    Product Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Hualan Biological
        17.9.1    Financial Analysis
        17.9.2    Product Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10     AMRESCO Inc
        17.10.1    Financial Analysis
        17.10.2    Product Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    CSL Behring
        17.11.1    Financial Analysis
        17.11.2    Product Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Mallinckrodt Pharmaceuticals 
        17.12.1    Financial Analysis
        17.12.2    Product Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
    17.13    BIOFAC A/S 
        17.13.1    Financial Analysis
        17.13.2    Product Portfolio
        17.13.3    Demographic Reach and Achievements
        17.13.4    Mergers and Acquisitions
        17.13.5    Certifications
    17.14    Biomed-Lublin S.A. 
        17.14.1    Financial Analysis
        17.14.2    Product Portfolio
        17.14.3    Demographic Reach and Achievements
        17.14.4    Mergers and Acquisitions
        17.14.5    Certifications
    17.15    Hualan Biological Engineering, Inc. 
        17.15.1    Financial Analysis
        17.15.2    Product Portfolio
        17.15.3    Demographic Reach and Achievements
        17.15.4    Mergers and Acquisitions
        17.15.5    Certifications
List not exhaustive
18    Global Thrombin Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

Key Questions Answered in the Report

The market attained a value of about USD 665 million in 2023, driven by the increasing prevalence of blood disorders such as hemophilia across the globe.

The market is anticipated to grow at a CAGR of 5.50% during the forecast period of 2024-2032, likely to reach a market value of USD 1075.9 million by 2032.

The increased expenditure on healthcare and the rising patient awareness are some of the factors contributing to the increasing market demand.

The growing application of thrombin-based products, including recombinant thrombin in the healthcare sector, is the major trend in the market. In April 2023, Baxter International Inc. announced the launch of Floseal + Recothrom, a novel flowable hemostat with a recombinant thrombin. Faster to prepare than FLOSEAL with human thrombin, the homeostat is manufactured using recombinant DNA technology.

The various products in the market are bovine, human, and recombinant thrombin.

Based on the dosage form, the market is segmented into powder form and solution form.

Major end users of thrombin include hospitals, diagnostic centers and clinics, academics, and research institutes, among others.

The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.

Key players involved in the market are Pfizer Inc., Johnson and Johnson, Baxter International, Inc., Shanghai RAAS Blood Products Co., Ltd., Japan Blood Products Organization, Mochida Pharmaceutical Co., Ltd, Haematologic Technologies Inc., GE Healthcare, Hualan Biological, AMRESCO Inc, CSL Behring, Mallinckrodt Pharmaceuticals, BIOFAC A/S, Biomed-Lublin S.A., and Hualan Biological Engineering, Inc.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER